Reduced hepatic extraction of palmitate in steatosis correlated to lower level of liver fatty acid binding protein

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 288, Issue 1 51-1, 2005, Pages

  Hung, Daniel Y ^a   Siebert, Gerhard A ^a   Chang, Ping ^a   Burczynski, Frank J ^b   Roberts, Michael S ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

17 ethynylestradiol; Hepatic palmitate disposition

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450; ETHINYLESTRADIOL; FATTY ACID BINDING PROTEIN; PALMITIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFUSION; FATTY ACID ANALYSIS; FATTY ACID METABOLISM; FEMALE; LIPID LIVER LEVEL; LIPID METABOLISM; LIVER FUNCTION; LIVER HISTOLOGY; LIVER LEVEL; LIVER SINUSOID; METABOLITE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; STEATOSIS;

ANIMALS; CARRIER PROTEINS; ESTROGENS; ETHINYL ESTRADIOL; FATTY ACID-BINDING PROTEINS; FATTY ACIDS; FATTY LIVER; FEMALE; LIVER; PALMITATES; RATS; RATS, WISTAR;

EID: 10844241705     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00196.2004     Document Type: Article

References (39)

1. Abumrad N, Coburn C, and Ibrahimi A. Membrane proteins implicated in long-chain fatty acid uptake by mammalian cells: CD36, FATP and FABPm. Biochim Biophys Acta 1441: 4-13, 1999.
2. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, and Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123: 134-140, 2002.
3. Burczynski FJ, Moran JB, and Cai ZS. Facilitated dissociation of albumin-fatty acid complexes by rat hepatocytes. J Pharmacol Exp Ther 267: 714-719, 1993.
4. Burczynski FJ, Zhang MN, Pavletic P, and Wang GQ. Role of fatty acid binding protein on hepatic palmitate uptake. Can J Physiol Pharmacol 75: 1350-1355, 1997.
5. Charlton M, Sreekumar R, Rasmussen D, Lindor K, and Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 35: 898-904, 2002.
6. Cheung K, Hickman PE, Potter JM, Walker NI, Jericho M, Haslam R, and Roberts MS. An optimized model for rat liver perfusion studies. J Surg Res 66: 81-89, 1996.
7. Contos MJ and Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol 9: 37-51, 2002.
8. Elmadhoun BM, Wang GQ, Kirshenbaum LA, and Burczynski FJ. Palmitate uptake by neonatal rat myocytes and hepatocytes. Role of extracellular protein. Eur J Biochem 268: 3145-3153, 2001.
9. 3H]palmitate to BSA. Am J Physiol Gastrointest Liver Physiol 275: G638-G644, 1998.
10. Goresky CA, Stremmel W, Rose CP, Guirguis S, Schwab AJ, Diede HE, and Ibrahim E. The capillary transport system for free fatty acids in the heart. Circ Res 74: 1015-1026, 1994.
11. Harrison SA and Di Bisceglie AM. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Drugs 63: 2379-2394, 2003.
12. Harrison SA, Kadakia S, Lang KA, and Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 97: 2714-2724, 2002.
13. Hung DY, Burczynski FJ, Chang P, Lewis A, Masci PP, Siebert GA, Anissimov YG, and Roberts MS. Fatty acid binding protein is a major determinant of hepatic pharmacokinetics of palmitate and its metabolites. Am J Physiol Gastrointest Liver Physiol 284: G423-G433, 2003.
14. Hung DY, Chang P, Weiss M, and Roberts MS. Structure-hepatic disposition relationships for cationic drugs in isolated perfused rat livers: transmembrane exchange and cytoplasmic binding process. J Pharmacol Exp Ther 297: 780-789, 2001.
15. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, and Leclercq I. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 38: 123-132, 2003.
16. Lowry O, Rosebrough N, Farr A, and Randall R. Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
17. Luxon BA. Inhibition of binding to fatty acid binding protein reduces the intracellular transport of fatty acids. Am J Physiol Gastrointest Liver Physiol 271: G113-G120, 1996.
18. Luxon BA, Holly DC, Milliano MT, and Weisiger RA. Sex differences in multiple steps in hepatic transport of palmitate support a balanced uptake mechanism. Am J Physiol Gastrointest Liver Physiol 274: G52-G61, 1998.
19. Luxon BA, Milliano MT, and Weisiger RA. Induction of hepatic cytosolic fatty acid binding protein with clofibrate accelerates both membrane and cytoplasmic transport of palmitate. Biochim Biophys Acta 1487: 309-318, 2000.
20. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, and Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917-923, 2003.
21. Matsubara T, Koike M, Touchi A, Tochino Y, and Sugeno K. Quantitative determination of cytochrome P-450 in rat liver homogenate. Anal Biochem 75: 596-603, 1976.
22. Mofrad PS and Sanyal AJ. Nonalcoholic fatty liver disease. Med Gen Med 5: 14, 2003.
23. Neuschwander-Tetri BA and Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37: 1202-1219, 2003.
24. Perez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G, Colina F, Arenas J, and Solis-Herruzo JA. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 38: 999-1007, 2003.
25. Pond SM, Davis CK, Bogoyevitch MA, Gordon RA, Weisiger RA, and Bass L. Uptake of palmitate by hepatocyte suspensions: facilitation by albumin? Am J Physiol Gastrointest Liver Physiol 262: G883-G894, 1992.
26. Poonawala A, Nair SP, and Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32: 689-692, 2000.
27. Reddy JK and Mannaerts GP. Peroxisomal lipid metabolism. Annu Rev Nutr 14: 343-370, 1994.
28. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 121: 710-723, 2001.
29. Roberts MS, Donaldson JD, and Rowland M. Models of hepatic elimination: comparison of stochastic models to describe residence time distributions and to predict the influence of drug distribution, enzyme heterogeneity, and systemic recycling on hepatic elimination. J Pharmacokinet Biopharm 16: 41-83, 1988.
30. Roberts MS, Fraser S, Wagner A, and McLeod L. Residence time distribution of solutes in the perfused rat liver using a dispersion model of hepatic elimination. J Pharmacokinet Biopharm 18: 209-234, 1990.
31. Sanchez Pozzi EJ, Crocenzi FA, Pellegrino JM, Catania VA, Luquita MG, Roma MG, Rodriguez Garay EA, and Mottino AD. Ursodeoxycholate reduces ethinylestradiol glucuronidation in the rat: role in prevention of estrogen-induced cholestasis. J Pharmacol Exp Ther 306: 279-286, 2003.
32. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, and Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 143: 500-505, 2003.
33. Simpson AE. The cytochrome P450 4 (CYP4) family. Gen Pharmacol 28: 351-359, 1997.
34. Weisiger RA. Saturable stimulation of fatty acid transport through model cytoplasm by soluble binding protein. Am J Physiol Gastrointest Liver Physiol 277: G109-G119, 1999.
35. Weisiger RA, Pond SM, and Bass L. Hepatic uptake of protein-bound ligands: extended sinusoidal perfusion model. Am J Physiol Gastrointest Liver Physiol 261: G872-G884, 1991.
36. Weisiger RA and Zucker SD. Transfer of fatty acids between intracellular membranes: roles of soluble proteins, distance, and time. Am J Physiol Gastrointest Liver Physiol. 282: G105-G115, 2002.
37. Weiss M and Roberts MS. Tissue distibution kinetics as a determinant of transit time dispersion of drugs in organs: application of a stochastic model for the rat hindlimb. J Pharmacokinet Biopharm 24: 173-196, 1996.
38. Wolfrum C, Buhlmann C, Rolf B, Borchers T, and Spener F. Variation of liver-type fatty acid binding protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the rate of fatty acid uptake. Biochim Biophys Acta 1437: 194-201, 1999.
39. Stremmel W, Pohl L, Ring A, and Herrmann T. A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids. Lipids 36: 981-989, 2001.